# A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

> **NCT05909852** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 372 (actual)

## Conditions studied

- Adalimumab

## Interventions

- **DRUG:** ABP 501-HCF
- **DRUG:** ABP 501-LCF

## Key facts

- **NCT ID:** NCT05909852
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-23
- **Primary completion:** 2021-11-24
- **Final completion:** 2021-11-24
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909852, "A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05909852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*